Gem citationer

Citação APA (7ª ed.)
Holida, M., Linhart, A., Longo, N., Wallace, E., Tøndel, C., Hughes, D., . . . Bernat, J. A. (2026). Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: Results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. BMC.
Citação do estilo Chicago (17ª ed.)
Holida, Myrl, et al. Long-term Efficacy and Safety of Pegunigalsidase Alfa Administered Every 4 Weeks in Adults with Fabry Disease: Results from Up to 5 Years of the BRIGHT F51 Phase III, Open-label Extension Study. BMC, 2026.
Citação MLA (9ª ed.)
Holida, Myrl, et al. Long-term Efficacy and Safety of Pegunigalsidase Alfa Administered Every 4 Weeks in Adults with Fabry Disease: Results from Up to 5 Years of the BRIGHT F51 Phase III, Open-label Extension Study. BMC, 2026.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.